Results 201 to 210 of about 1,761,594 (315)
Annual reports from division of biochemistry, central laboratory for medical science
openalex +2 more sources
An Evidence-Supported Medical Laboratory Science Program Admissions Selection Process
Janice M. Conway-Klaassen
semanticscholar +1 more source
Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh+5 more
wiley +1 more source
Xiaolong Tang,1,2,* Yong Liang,3,* Yongqiang Zhu,1,4,* Chunmei Xie,5 Aixia Yao,1 Li Chen,1 Qinglin Jiang,1 Tingting Liu,1 Xiaoyu Wang,1 Yunyun Qian,1 Jia Wei,1 Wenxuan Ni,1 Jingjing Dai,1 Zhenyou Jiang,6,7,* Wei Hou2,* 1Clinical Laboratory, Huainan ...
Tang X+14 more
doaj
307 The Importance of Traditional Education in Medical Laboratory Science [PDF]
Shane Lawson, Carlo Ledesma
openaire +2 more sources
RKIP, a metastasis suppressor protein, modulates key oncogenic pathways in lung adenocarcinoma. In silico analyses linked low RKIP expression to poor survival. Functional studies revealed RKIP overexpression reduces tumor aggressiveness and enhances sensitivity to EGFR‐targeted therapies, while its loss promotes resistance.
Ana Raquel‐Cunha+10 more
wiley +1 more source
AZD9291 has shown promise in targeted cancer therapy but is limited by resistance. In this study, we employed metabolic labeling and LC–MS/MS to profile time‐resolved nascent protein perturbations, allowing dynamic tracking of drug‐responsive proteins. We demonstrated that increased NNMT expression is associated with drug resistance, highlighting NNMT ...
Zhanwu Hou+5 more
wiley +1 more source
Tanya S. Beard+3 more
semanticscholar +1 more source